Spectral Diagnostics (OTCMKTS:EDTXF) Announces Quarterly Earnings Results

Spectral Diagnostics (OTCMKTS:EDTXF) released its quarterly earnings results on Friday. The company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01), Zacks reports.

Spectral Diagnostics Price Performance

Shares of Spectral Diagnostics stock traded up $0.01 during midday trading on Friday, reaching $1.03. The company had a trading volume of 13,337 shares, compared to its average volume of 7,337. The stock has a fifty day moving average price of $0.99 and a 200 day moving average price of $0.99. The firm has a market cap of $301.64 million, a PE ratio of -8.57 and a beta of 0.09. Spectral Diagnostics has a fifty-two week low of $0.58 and a fifty-two week high of $1.31.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.